Immunitybio announces authorization to proceed with phase 1/2/3 randomized trial in south africa of their dual-antigen t-cell vaccine as a universal boost in previously vaccinated participants against covid-19

Culver city, calif.--(business wire)--immunitybio, inc., (nasdaq: ibrx), a publicly traded immunotherapy company, today announced authorization from the south africa health products regulatory authority (sahpra) to proceed with the south africa sisonke t-cell universal boost trial. the phase 1/2/3 study, which will begin in q3 2021, is designed to evaluate had5 spike + nucleocapsid (s+n) as a boost for south african healthcare workers previously vaccinated with an s-only vaccine. “with the viru
IBRX Ratings Summary
IBRX Quant Ranking